This study presents Frost & Sullivan’s overall market and segment-wise revenue forecasts of the global small molecule contract development and manufacturing organization (CDMO) industry. It highlights key growth opportunities for small molecule CDMOs based on the main evolution in their business models and strategic approaches as well as those of pharmaceutical sponsors. The study segments the market into two categories based on product type: Active pharmaceutical ingredients (API) manufacturing (API/drug substance) and finished dosage form (FDF) manufacturing (FDF/drug product). API is further segmented into innovator and generic APIs, while FDF is segmented into oral, semi-solid/liquid, and injectable forms. The market forecasts in this report are for 2020–2026, capturing key market developments such as capacity expansions, mergers, acquisitions, and expanding service offerings that are set to affect the overall small molecule CDMO market growth.
Other discussions in the study include:
• The impact of strategic imperatives on the industry
• Growth drivers and restraints
• Comprehensive insights on the competitive landscape
• Revenue share estimates of top market participants
• Strategic analysis of market developments in service offerings and business models
Take your first step towards achieving growth-centric solutions with our
Growth Pipeline Dialog™. Speak to our industry experts in a complimentary open discussion that will spark innovative thinking and growth opportunities that will benefit your organization.
